We identified three lipid-metabolism-related genes (ME1, MED10, and MED22) that are upregulated in HCC tissues, and established a 3-gene signature-based risk model that can accurately predict HCC patient prognosis. This evidence concerns the gene MED10 and hepatocellular carcinoma.